Bausch + Lomb Co. (NYSE:BLCO) Holdings Raised by Raymond James & Associates

Raymond James & Associates grew its stake in shares of Bausch + Lomb Co. (NYSE:BLCO) by 33.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 192,326 shares of the company’s stock after purchasing an additional 47,914 shares during the period. Raymond James & Associates owned about 0.05% of Bausch + Lomb worth $3,281,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of BLCO. Barclays PLC purchased a new stake in shares of Bausch + Lomb during the fourth quarter valued at $30,000. State of Wyoming purchased a new stake in shares of Bausch + Lomb during the fourth quarter valued at $32,000. BNP Paribas Arbitrage SNC purchased a new stake in Bausch + Lomb in the 3rd quarter worth about $33,000. Tower Research Capital LLC TRC purchased a new stake in Bausch + Lomb in the 3rd quarter worth about $87,000. Finally, Legal & General Group Plc purchased a new stake in Bausch + Lomb in the 2nd quarter worth about $153,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

Bausch + Lomb Stock Performance

Shares of BLCO stock opened at $14.24 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.74 and a quick ratio of 1.09. Bausch + Lomb Co. has a fifty-two week low of $13.62 and a fifty-two week high of $21.95. The stock’s 50-day moving average is $15.87 and its two-hundred day moving average is $15.85. The firm has a market cap of $5.00 billion, a P/E ratio of -19.24, a PEG ratio of 1.45 and a beta of 0.36.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.07. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.11 billion. Bausch + Lomb had a positive return on equity of 3.70% and a negative net margin of 6.27%. The firm’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.23 EPS. Analysts predict that Bausch + Lomb Co. will post 0.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BLCO shares. Royal Bank of Canada set a $20.00 price objective on Bausch + Lomb and gave the stock an “outperform” rating in a research note on Friday, December 29th. Evercore reduced their price objective on Bausch + Lomb from $17.00 to $16.50 and set an “in-line” rating for the company in a research note on Thursday, February 22nd. Wells Fargo & Company increased their price objective on Bausch + Lomb from $21.00 to $23.00 and gave the stock an “overweight” rating in a research note on Thursday, February 22nd. Evercore ISI increased their price objective on Bausch + Lomb from $16.50 to $17.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Finally, Barclays increased their price objective on Bausch + Lomb from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Bausch + Lomb has an average rating of “Moderate Buy” and a consensus price target of $19.68.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.